NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 177 filers reported holding NEKTAR THERAPEUTICS in Q1 2016. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $394,000 | -55.0% | 8,068 | -2.0% | 0.28% | -58.2% |
| Q1 2018 | $875,000 | -16.5% | 8,230 | -53.1% | 0.67% | -17.7% |
| Q4 2017 | $1,048,000 | +5.6% | 17,542 | -57.5% | 0.82% | -6.8% |
| Q3 2017 | $992,000 | +22.5% | 41,316 | -0.3% | 0.88% | +22.8% |
| Q2 2017 | $810,000 | -18.0% | 41,420 | -1.6% | 0.71% | -7.0% |
| Q1 2017 | $988,000 | +91.1% | 42,109 | -0.0% | 0.77% | +92.5% |
| Q4 2016 | $517,000 | -31.3% | 42,124 | -3.9% | 0.40% | -35.2% |
| Q3 2016 | $753,000 | +13.6% | 43,851 | -6.0% | 0.62% | +3.5% |
| Q2 2016 | $663,000 | -70.9% | 46,626 | -71.8% | 0.60% | -69.1% |
| Q1 2016 | $2,277,000 | -25.2% | 165,584 | -8.3% | 1.92% | -13.0% |
| Q4 2015 | $3,043,000 | +47.5% | 180,601 | -4.0% | 2.21% | +50.6% |
| Q3 2015 | $2,063,000 | +184.2% | 188,220 | +224.2% | 1.47% | +220.0% |
| Q2 2015 | $726,000 | +53.8% | 58,053 | +35.2% | 0.46% | +67.5% |
| Q1 2015 | $472,000 | – | 42,938 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |